Login to Your Account

Praluent pursuant? FDA word due soon; Amgen's Repatha scores EU nod

By Randy Osborne
Staff Writer

Tuesday, July 21, 2015
Analysts mulled what the approval in the European Union (EU) of Amgen Inc.'s cholesterol drug Repatha (evolocumab) might mean for the compound's fate in the U.S., and for same-class competitor Praluent (alirocumab) from Regeneron Pharmaceuticals Inc. and Sanofi SA in both regions.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription